VA
XFOR icon

VR Adviser’s X4 Pharmaceuticals XFOR Stock Holding History

VR Adviser’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Buy
+330,525
New +$1.24M 0.05% 33

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

VR Adviser's XFOR Position: Q1 2026 in Review

VR Adviser opened a new position in X4 Pharmaceuticals (XFOR) in Q1 2026: 330,525 shares worth $1.37M. The stake represents 0.05% of the portfolio and ranks #33 among its holdings.

84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • VR Adviser held 330,525 shares of X4 Pharmaceuticals worth $1.37M as of Q1 2026.
  • X4 Pharmaceuticals was a new VR Adviser position in Q1 2026.
  • X4 Pharmaceuticals made up 0.05% of VR Adviser's portfolio in Q1 2026, its #33 holding.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.